Scholarlink

<p>Bladder cancer is one of the most common malignancies worldwide, impacting public health systems due to its high rate of recurrence. Metabolic alterations enable the identification of novel, needed prognostic markers and therapeutic vulnerabilities for precision oncology. Here, we use a systems metabolomics approach that integrates metabolic functional data with multi-omics, transcriptomics and metabolomics, through biostatistics and mathematical modelling to characterise metabolic rearrangements associated with <i>FGFR3</i> oncogenic activation, one of the most frequent lesions in bladder cancer. The analyses conducted on a panel of five human bladder cancer cell lines reveal a significant correlation between <i>FGFR3</i> alterations and the acquisition of a predominantly oxidative, poorly migratory phenotype, regardless of tumour progression. These preclinical results, validated through FGFR3 and oxidative phosphorylation pharmacological inhibition, and computational analysis on bladder cancer cell line and patient publicly available datasets, support the therapeutic potential of targeting oxidative metabolism in <i>FGFR3</i>-altered tumours, including more aggressive subtypes.</p><p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

FGFR3 oncogenic activation drives oxidative metabolic reprogramming in bladder cancer: a systems metabolomics approach

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月23日

查看全文
  • Giacomo Ducci,
  • Giorgia Ciufolini,
  • Gloria Campioni,
  • Valentina Pasquale,
  • Giulia Gigliotti,
  • Simone Ponzetto,
  • Daniele Benedetti,
  • Bruno Giovanni Galuzzi,
  • Deborah D’Aliberti,
  • Silvia Spinelli,
  • Vrunda Satasiya,
  • Elisa Ventura,
  • Chiara Raggi,
  • Riccardo Vago,
  • Marcella Bonanomi,
  • Daniela Gaglio,
  • Antonio Giordano,
  • Andrea Morrione,
  • Chiara Damiani,
  • Rocco Piazza,
  • Daniel Oscar Cicero,
  • Marco Vanoni,
  • Greta Petrella,
  • Elena Sacco

摘要

Bladder cancer is one of the most common malignancies worldwide, impacting public health systems due to its high rate of recurrence. Metabolic alterations enable the identification of novel, needed prognostic markers and therapeutic vulnerabilities for precision oncology. Here, we use a systems metabolomics approach that integrates metabolic functional data with multi-omics, transcriptomics and metabolomics, through biostatistics and mathematical modelling to characterise metabolic rearrangements associated with FGFR3 oncogenic activation, one of the most frequent lesions in bladder cancer. The analyses conducted on a panel of five human bladder cancer cell lines reveal a significant correlation between FGFR3 alterations and the acquisition of a predominantly oxidative, poorly migratory phenotype, regardless of tumour progression. These preclinical results, validated through FGFR3 and oxidative phosphorylation pharmacological inhibition, and computational analysis on bladder cancer cell line and patient publicly available datasets, support the therapeutic potential of targeting oxidative metabolism in FGFR3-altered tumours, including more aggressive subtypes.